Overview

Update
IPO / Stock
Went Public on Jul 2, 2004 / NASDAQ:MNTA
Total Equity Funding
$39.5M in 2 Rounds from 5 Investors
Headquarters:
Cambridge, MA
Description:
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Founders:
, ,
Categories:
Pharmaceutical, Health Care, Biotechnology
Website:
http://www.momentapharma.com
Social:

Company Details

Update

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Funding Rounds (2) - $39.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Mar, 2004$20.5M / Series C5
May, 2003$19M / Series B4

Current Team (4)

Update

Offices/Locations (1)

Update
  • Headquarters

    675 West Kendall Street

    Cambridge, MA 02142

    USA

Past Team (10)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos